Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Total Debt (2022 - 2025)

Historic Total Debt for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $207.1 million.

  • Phathom Pharmaceuticals' Total Debt rose 1784.79% to $207.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $207.1 million, marking a year-over-year increase of 1784.79%. This contributed to the annual value of $201.4 million for FY2024, which is 4611.58% up from last year.
  • Phathom Pharmaceuticals' Total Debt amounted to $207.1 million in Q3 2025, which was up 1784.79% from $205.1 million recorded in Q2 2025.
  • Over the past 5 years, Phathom Pharmaceuticals' Total Debt peaked at $207.1 million during Q3 2025, and registered a low of $91.0 million during Q1 2022.
  • Over the past 4 years, Phathom Pharmaceuticals' median Total Debt value was $137.8 million (recorded in 2023), while the average stood at $141.3 million.
  • In the last 5 years, Phathom Pharmaceuticals' Total Debt surged by 573.19% in 2023 and then soared by 7833.57% in 2024.
  • Over the past 4 years, Phathom Pharmaceuticals' Total Debt (Quarter) stood at $95.3 million in 2022, then skyrocketed by 44.69% to $137.8 million in 2023, then surged by 46.12% to $201.4 million in 2024, then increased by 2.82% to $207.1 million in 2025.
  • Its Total Debt stands at $207.1 million for Q3 2025, versus $205.1 million for Q2 2025 and $203.2 million for Q1 2025.